Peritoneal Metastases from Colorectal Cancer: Treatment Principles and Perspectives

Diane Goéré; Isabelle Sourrouille; Maximiliano Gelli; Léonor Benhaim; Matthieu Faron; Charles Honoré

doi:10.1016/j.soc.2018.02.011

Peritoneal Metastases from Colorectal Cancer: Treatment Principles and Perspectives

Diane Goéré, Isabelle Sourrouille, Maximiliano Gelli, Léonor Benhaim, Matthieu Faron, Charles Honoré

Research output: Contribution to journal › Review article › peer-review

25 Citations (Scopus)

Abstract

Peritoneal metastases are the third most common site of recurrence of colorectal cancer. Diagnosis is difficult and often made at an advanced stage even on imaging. Curative treatment relies on complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC), which dramatically improves survival in selected patients. Main prognostic factors are based on the extent of the peritoneal disease and the completeness of surgery. Therefore, identifying patients at high risk of developing peritoneal metastases with the aim of diagnosing and treating patients at an early stage appears crucial. Proactive attitude and prophylactic treatment based on HIPEC are being evaluated on clinical trials.

Original language	English
Pages (from-to)	563-583
Number of pages	21
Journal	Surgical Oncology Clinics of North America
Volume	27
Issue number	3
DOIs	https://doi.org/10.1016/j.soc.2018.02.011
Publication status	Published - 1 Jul 2018

Keywords

Carcinomatosis
Colorectal cancer
HIPEC
Peritoneal metastases

Access to Document

10.1016/j.soc.2018.02.011

Cite this

@article{d670be204d644dcf9ee8a9152e5b4f39,

title = "Peritoneal Metastases from Colorectal Cancer: Treatment Principles and Perspectives",

abstract = "Peritoneal metastases are the third most common site of recurrence of colorectal cancer. Diagnosis is difficult and often made at an advanced stage even on imaging. Curative treatment relies on complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC), which dramatically improves survival in selected patients. Main prognostic factors are based on the extent of the peritoneal disease and the completeness of surgery. Therefore, identifying patients at high risk of developing peritoneal metastases with the aim of diagnosing and treating patients at an early stage appears crucial. Proactive attitude and prophylactic treatment based on HIPEC are being evaluated on clinical trials.",

keywords = "Carcinomatosis, Colorectal cancer, HIPEC, Peritoneal metastases",

author = "Diane Go{\'e}r{\'e} and Isabelle Sourrouille and Maximiliano Gelli and L{\'e}onor Benhaim and Matthieu Faron and Charles Honor{\'e}",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2018",

month = jul,

day = "1",

doi = "10.1016/j.soc.2018.02.011",

language = "English",

volume = "27",

pages = "563--583",

journal = "Surgical Oncology Clinics of North America",

issn = "1055-3207",

number = "3",

}

TY - JOUR

T1 - Peritoneal Metastases from Colorectal Cancer

T2 - Treatment Principles and Perspectives

AU - Goéré, Diane

AU - Sourrouille, Isabelle

AU - Gelli, Maximiliano

AU - Benhaim, Léonor

AU - Faron, Matthieu

AU - Honoré, Charles

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Peritoneal metastases are the third most common site of recurrence of colorectal cancer. Diagnosis is difficult and often made at an advanced stage even on imaging. Curative treatment relies on complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC), which dramatically improves survival in selected patients. Main prognostic factors are based on the extent of the peritoneal disease and the completeness of surgery. Therefore, identifying patients at high risk of developing peritoneal metastases with the aim of diagnosing and treating patients at an early stage appears crucial. Proactive attitude and prophylactic treatment based on HIPEC are being evaluated on clinical trials.

AB - Peritoneal metastases are the third most common site of recurrence of colorectal cancer. Diagnosis is difficult and often made at an advanced stage even on imaging. Curative treatment relies on complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC), which dramatically improves survival in selected patients. Main prognostic factors are based on the extent of the peritoneal disease and the completeness of surgery. Therefore, identifying patients at high risk of developing peritoneal metastases with the aim of diagnosing and treating patients at an early stage appears crucial. Proactive attitude and prophylactic treatment based on HIPEC are being evaluated on clinical trials.

KW - Carcinomatosis

KW - Colorectal cancer

KW - HIPEC

KW - Peritoneal metastases

UR - http://www.scopus.com/inward/record.url?scp=85048838175&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2018.02.011

DO - 10.1016/j.soc.2018.02.011

M3 - Review article

C2 - 29935690

AN - SCOPUS:85048838175

SN - 1055-3207

VL - 27

SP - 563

EP - 583

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

IS - 3

ER -

Peritoneal Metastases from Colorectal Cancer: Treatment Principles and Perspectives

Abstract

Keywords

Access to Document

Other files and links

Cite this